Transfusion of allogenic cord blood to patients with multiple myeloma: safety analysis and influence on the immunophenotype of blood lymphocytes in the early period
- Authors: Tyumina O.V.1,2, Davydkin I.L.2, Gritsenko T.A.2, Trusova L.M.1, Tyumin I.V.1,3, Bogush V.V.2, Sokolova V.V.2, Gusarova E.A.2, Chibashova A.V.2, Limareva L.V.2
-
Affiliations:
- Dynasty Samara Regional Medical Center
- Samara State Medical University
- A. Tsyb Medical Radiological Research Center, Branch of the National Medical Research Center for Radiology
- Issue: Vol 27, No 2 (2024)
- Pages: 299-306
- Section: SHORT COMMUNICATIONS
- URL: https://journals.rcsi.science/1028-7221/article/view/263691
- DOI: https://doi.org/10.46235/1028-7221-16866-TOA
- ID: 263691
Cite item
Full Text
Abstract
Severe immune dysfunction occurs in the majority of cancer patients. One of the methods for overcoming immune disorders is transplantation of peripheral blood hematopoietic stem cells, both autologous and allogeneic, and transfusion of allogeneic natural killer cells (NK cells). Umbilical cord blood is a known source of not only hematopoietic stem cells (HSCs) but also NK cells, characterized by the rapid availability of blood samples from public cord blood banks. Purpose of the study: to analyze the safety of simultaneous transfusion of three allogeneic cord blood to patients with relapsed/refractory multiple myeloma in the early period (7 days after administration), and also to study the response of subpopulations of peripheral blood lymphocytes of patients to this intervention.
The pilot study included 10 patients (7 men and 3 women) with relapsed/refractory multiple myeloma who had previously received more than 3 lines of therapy. The age of the patients was 59.4±3.4 years; all of them received a single transfusion of three allogeneic samples of umbilical cord blood with an average dose of leukocytes of 60.50±8.2 × 108 (NK cells – 4.36±1.2 × 108) per one patient. A total of 30 samples of umbilical cord blood, alloreactive for KIR receptors of the receptor-ligand type, were transfused. The selection of HSCs concentrates was carried out in the umbilical cord blood bank of the Dynasty Medical Center. Before transfusion of umbilical cord blood, patients received cyclophosphamide 5 mg/kg. After transfusion, patients received five subcutaneous injections of IL-2 (roncoleukin) in the amount of 1 million units per day. Observation at the time of assessment of preliminary results: 7 days after transfusion. Analysis of the immunophenotype of patient lymphocytes was studied twice: on the day of transfusion before the start of the protocol and 7 days after transfusion of umbilical cord blood.
No early adverse reactions to transfusions were observed.
Simultaneous transfusion of three allogeneic cord blood to patients with relapsed/refractory multiple myeloma is a safe procedure. There are no adverse reactions, serious adverse events, or significant reactions/changes in the immunophenotype of patient lymphocytes in the early observation period within 7 days after the intervention.
Full Text
##article.viewOnOriginalSite##About the authors
O. V. Tyumina
Dynasty Samara Regional Medical Center; Samara State Medical University
Email: centr123@bk.ru
PhD, MD (Medicine), Director; Professor of the Department of Hospital Therapy
Russian Federation, Samara; SamaraI. L. Davydkin
Samara State Medical University
Email: centr123@bk.ru
PhD, MD (Medicine), Professor, Head, Department of Hospital Therapy with Courses of Polyclinic Therapy and Transfusiology
Russian Federation, SamaraT. A. Gritsenko
Samara State Medical University
Email: centr123@bk.ru
PhD (Medicine), Deputy Director, Research Institute of Hematology
Russian Federation, SamaraL. M. Trusova
Dynasty Samara Regional Medical Center
Email: centr123@bk.ru
Head, Department of Immunology
Russian Federation, SamaraI. V. Tyumin
Dynasty Samara Regional Medical Center; A. Tsyb Medical Radiological Research Center, Branch of the National Medical Research Center for Radiology
Email: centr123@bk.ru
Postgraduate Student, Department of Clinical Immunology; Oncologist
Russian Federation, Samara; ObninskV. V. Bogush
Samara State Medical University
Email: centr123@bk.ru
Biologist, Clinical Diagnostic Laboratory of the Clinics
Russian Federation, SamaraV. V. Sokolova
Samara State Medical University
Email: centr123@bk.ru
Student
Russian Federation, SamaraE. A. Gusarova
Samara State Medical University
Email: centr123@bk.ru
Student
Russian Federation, SamaraA. V. Chibashova
Samara State Medical University
Email: centr123@bk.ru
Assistant Professor, Department of Hospital Therapy with a Course of Outpatient Therapy and Transfusiology
Russian Federation, SamaraL. V. Limareva
Samara State Medical University
Author for correspondence.
Email: centr123@bk.ru
PhD, MD (Biology), Professor, Department of General and Clinical Microbiology, Immunology and Allergology
Russian Federation, SamaraReferences
- Тюмина О.В., Волчков С.Е., Овчинников П.А. Применение гематопоэтических стволовых клеток пуповинной крови // Гены и Клетки, 2019. Т. 14, № 3. С. 236-237. [Tyumina O.V., Volchkov S.E., Ovchinnikov P.A. Application of cord blood hematopoietic stem cells. Geny I Kletki = Genes and Cells, 2019, Vol. 14, no. 3, pp. 236-237. (In Russ.)]
- Boussiotis V. Molecular and biochemical aspects of the PD-1checkpoint path. New Eng. J. Med., 2016, Vol. 375, pp. 1767-1778.
- Clara J.A., Childs R.W. Harnessing natural killer cells for the treatment of multiple myeloma. Semin. Oncol., 2022, Vol. 49, no. 1, pp. 69-85.
- Dalle J.H., Menezes J., Wagner E., Blagdon M., Champagne J., Champagne M.A., Duval M. Characterization of cord blood natural killer cells: implications for transplantation and neonatal infections. Pediatr. Res., 2005, Vol. 57, pp. 649-655.
- Damele L., Spaggiari G.M., Parodi M., Mingari M.C., Vitale M., Vitale C. Cord blood-derived natural killer cell exploitation in immunotherapy protocols: more than a promise? Cancers, 2022, Vol. 14, 4439. doi: 10.3390/cancers14184439.
- Escobedo-Cousin M., Jackson N., Laza-Briviesca R., Ariza-McNaughton L., Luevano M., Derniame S., Querol S., Blundell M., Thrasher A., Soria B., Cooper N., Bonnet D., Madrigal A., Saudemont A. Natural killer cells improve hematopoietic stem cell engraftment by increasing stem cell clonogenicity in vitro and in a humanized mouse model. PLoS One, 2015, Vol. 10, 0138623. doi: 10.1371/journal.pone.0138623.
- Mehta R.S., Randolph B., Daher M., Rezvani K. NK cell therapy for hematologic malignancies. Int. J. Hematol., 2018, Vol. 107, no. 3, pp. 262-270.
- Morvan M., Lanier L. NK cells and cancer: you can teach innate cells new tricks. Nat. Rev. Cancer, 2016, Vol. 16, pp. 7-19.
- Miller J.S., Soignier Y., Panoskaltsis-Mortari A., McNearney S.A., Yun G.H., Fautsch S.K., McKenna D., Le C., Defor T.E., Burns L.J., Orchard P.J., Blazar B.R., Wagner J.E., Slungaard A., Weisdorf D.J., Okazaki I.J., McGlave P.B. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood, 2005, Vol. 105, no. 8, pp. 3051-3057.
- Romee R., Rosario M., Berrien-Elliott M.M., Wagner J.A., Jewell B.A., Schappe T., Leong J.W., Abdel-Latif S., Schneider S.E., Willey S., Neal C.C., Yu L., Oh S.T., Lee Y.-S., Mulder A., Claas F., Cooper M.A., Fehniger T.A. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci. Transl. Med., 2016, Vol. 8, 357ra123. doi: 10.1126/scitranslmed.aaf2341.
- Rubnitz J.E., Inaba H., Ribeiro R.C., Pounds S., Rooney B., Bell T., Pui C.-H., Leung W. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J. Clin. Oncol., 2010, Vol. 28, pp. 955-959.
- Sarvaria A., Jawdat D., Madrigal J.A., Saudemont A. Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications. Front. Immunol., 2017, Vol. 8, 329. doi: 10.3389/fimmu.2017.00329.
- Sánchez-Martínez D., Allende-Vega N., Orecchioni S., Talarico G., Cornillon A., Vo D., Rene C., Lu Z.-Y., Krzywinska E., Anel A. Expansion of allogeneic NK cells with efficient antibody-dependentcell cytotoxicity against multiple tumors. Theranostics, 2018, Vol. 8, no. 14, pp. 3856-3869.
- Verneris M.R., Mille J.S. The Phenotypic and Functional Characteristics of Umbilical Cord Blood and Peripheral Blood Natural Killer Cell. Br. J. Haematol., 2009, Vol. 147, no. 2, pp. 185-191.
